NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
February 5, 2024
BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc.,